Gyre Therapeutics signs new employment agreements with CEO and CFO

Gyre Therapeutics, Inc. disclosed in an 8-K filing that on October 16, 2026, it entered into employment agreements with its two top executives. The filing states that Gyre entered into an employment agreement with Ying Luo, Ph.D., to continue to serve as Gyre's Chief Executive Officer.¹ Under that agreement, Dr. Luo's employment is at-will, with an annual base salary of $500,000 and an annual bonus to be determined by the Board or Compensation Committee, targeted at $150,000 for 2026.¹

The filing also states that Gyre entered into an employment agreement with Thomas Eastling to continue to serve as Gyre's Chief Financial Officer.¹ His agreement sets at-will employment with an annual base salary of $339,066 and an annual bonus target of $70,000 for 2026.¹

Both agreements include severance terms. If either executive is terminated without "Cause" or resigns for "Good Reason" outside a change-of-control window, Luo would receive base salary paid in installments over six months, up to twelve months of COBRA premium reimbursement, and accelerated vesting of equity awards scheduled to vest in the following twelve months¹, with Eastling entitled to the same structure of six months' base salary, up to twelve months of COBRA reimbursement, and accelerated vesting of equity scheduled to vest within twelve months.¹

If such a termination occurs within three months before or twelve months after a change of control, Luo would instead receive a lump sum equal to his base salary and target bonus for the termination year, up to twelve months of COBRA reimbursement, and full accelerated vesting of all outstanding equity awards¹, with Eastling receiving the equivalent lump sum of base salary and target bonus, up to twelve months of COBRA reimbursement, and full vesting acceleration of all outstanding equity awards.¹

The agreements were filed as Exhibits 10.1 and 10.2 to the 8-K, which was signed by Eastling as CFO on October 22, 2026.